Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
Matinas Well Positioned For June Data Read Outs
Article By:
Jason Napodano
Tuesday, May 16, 2017 2:50 PM EDT
Matinas BioPharma Holdings, Inc. reported financial results for the first quarter ending March 31, 2017. The company also provided an update on anti-infective drug candidates, MAT2203 and MAT2501.
MAT2501 Phase 1 Data Look Good, Shares Look Attractive
Article By:
Jason Napodano
Wednesday, March 29, 2017 10:09 AM EDT
Matinas Biopharma's stock is cheap and I can easily see Matinas getting taken out at much higher levels - like most anti-infectant companies do - perhaps after the pipeline matures a bit.
In this article: MTNB
Matinas Expands Pipeline, Moves MAT2501 Into Phase 1
Article By:
Jason Napodano
Monday, December 12, 2016 1:07 PM EDT
Matinas BioPharma is vastly undervalued at today's level of only $85 million. My valuation for the company's product MAT2203 is $400 million.
In this article: MTNB
Matinas Initiates Important Phase 2 Study With MAT2203
Article By:
Jason Napodano
Monday, November 21, 2016 1:22 PM EDT
Matinas BioPharma Holdings, Inc. announced the commencement of dosing in a Phase 2 clinical study examining MAT2203 in patients with vulvovaginal candidiasis (VVC).
In this article: MTNB
Matinas Biopharma Is Highly Undervalued
I agree that $MTNB is undervalued. There is a good buying opportunity here.
Matinas Biopharma Is Highly Undervalued
What's with your dislike of $MTNB? I found the article to be quite impressive.
Matinas Biopharma Is Highly Undervalued
$MTNB sounds like they have a real advantage over the competition.